Dr. Shadman on the Emergence of Third-Generation BTK Inhibitors in CLL


In Partnership With:

Mazyar Shadman, MD, discusses the emergence of third-generation BTK inhibitors in chronic lymphocytic leukemia.

Mazyar Shadman, MD, a physician and associate professor in the Divisions of Medical Oncology and Clinical Research at Seattle Cancer Care Alliance, discusses the emergence of third-generation BTK inhibitors in chronic lymphocytic leukemia (CLL).

During the 2020 ASH Annual Meeting and Exposition, findings from the phase 1/2 BRUIN study demonstrated promising efficacy with the third-generation, highly selective BTK inhibitor pirtobrutinib (LOXO-305) in heavily pretreated patients with CLL or small lymphocytic lymphoma.

In addition to the relapsed/refractory setting, LOXO-305 should be evaluated for patients with newly diagnosed CLL, says Shadman. Moreover, the combination of LOXO-305 plus venetoclax (Venclexta) and rituximab (Rituxan) is being evaluated in the BRUINN CLL-322 trial for patients with relapsed/refractory disease, Shadman explains.

LOXO-305 could have clinical utility in settings where current BTK inhibitors are not considered optimal, Shadman says. In addition, LOXO-305 appears to confer less toxicity compared with other BTK inhibitors, which makes it a potentially useful agent for other combination approaches, Shadman says.

Finally, other third-generation BTK inhibitors are under investigation in the CLL pipeline, concludes Shadman.

Related Videos
Jeffery Auletta, MD, The Ohio State University College of Medicine
Betty Hamilton, MD, Cleveland Clinic
Chul Kim, MD, MPH
Neil D. Gross, MD, FACS
Dae Won Kim, MD, Gastrointestinal Oncology Program, Moffitt Cancer Center
Muhamad Alhaj Moustafa, MD, MS, hematologist, medical oncologist, Departments of Hematology and Oncology (Medical), Mayo Clinic
Reshma Jagsi, MD, DPhil, Emory University
Chandler H. Park, MD, FACP, Norton Health
Salman R. Punekar, MD, Mayo Clinic
Michael J. Overman, MD, The University of Texas MD Anderson Cancer Center,